This is a corrected version of STEPS that appeared in print.
Am Fam Physician. 2023;107(5):545-546
Related Letter to the Editor: Considerations for Implementing Cabotegravir (Apretude) as PrEP for HIV Infection
Author disclosure: No relevant financial relationships.
Cabotegravir (Apretude) is an extended-release injectable HIV type 1 (HIV-1) antiretroviral integrase strand transfer inhibitor. Cabotegravir is labeled for use in adults and adolescents weighing at least 35 kg (77 lb) who are HIV-negative but at risk of HIV-1. It is used as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection, the most common form of HIV.1
| Drug | Dosage | Dose form | Cost per dose* |
|---|---|---|---|
| Cabotegravir (Apretude) | Single 600-mg intramuscular injection First two doses given one month apart After initiation doses, subsequent injections given every two months† | Single-dose vial: 600 mg per 3 mL (200 mg per mL) | $4,000 (only available at select specialty pharmacies) |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
